Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 3Phase 1 3Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Non-Small Cell Lung Cancer × Thoracic × Clear all
NCT05785767 2026-01-22

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

Phase 2/3 Active not recruiting
850 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡